1. Physical Chemistry of Surfaces;Adamson,1999
2. AGL9909 study, 2000. A six-month, open label, fixed dose study to evaluate the safety, tolerance, pharmacokinetics and endocrine efficacy of two doses of LA-2550 22.5mg in patients with advanced prostate cancer. Eligard® product information, http://products.sanofi-aventis.us/eligard/eligard_225.html, downloaded on January 23, 2008.
3. Albayrak, C., 2005. Induced phase transition method for the production of microparticles containing hydrophobic active agents. US Patent 6,899,898 (31 May).
4. Molecular biointeractions of biomedical polymers with extracellular exudate and inflammatory cells and their effects on the biocompatibility, in vivo;Ali;Biomaterials,1994
5. New drug salt formation in biodegradable microspheres;Al-Maaieh;Int. J. Pharm.,2005